Cerdulatinib, an oral small-molecule inhibitor of spleen tyrosine kinase (SYK), JAK1 and JAK3, caused adverse events (AEs) in 100% of PTCL and CTCL patients (120). This evidence concerns the gene SYK and mature T-cell and NK-cell non-Hodgkin lymphoma.